The sharp rise in interest in weight loss medications presents both solutions and challenges for leaders in the healthcare space. Host and Aon’s Senior Vice President, National Pharmacy Practice Leader, Tracy Spencer, is joined by Michael Manolakis, Aon’s senior vice president, clinical innovation leader, National Pharmacy Practice, for a look at the current and future state of pharmacy challenges faced by plan sponsors in relation to the treatments, known as GLP-1s.[2:10] Distinguishing characteristics and challenges of GLP-1s[7:18] Balancing the fairness of coverage with the inappropriate utilization of drugs[11:30] Quality control and safety concerns in light of demands[18:05] ROI considerations for long term investment gains[19:26] Holistic fairness and equity of coverage in these patient support elements[26:15] A high level summary of considerations for employersAdditional Resources:Aon’s websiteAon’s Pharmacy Solutions LinkedInAon’s Pharmacy Benefit Consulting Aon’s Rx CoalitionTweetables:“Employers, over the course of last year, have been wrestling with and raising some very challenging questions about how to manage these drugs.” — Michael Manolakis“The impact of unofficial celebrity endorsements via social media has been astonishing.” — Michael Manolakis“These are really challenging questions here about how we treat obesity and how we think about obesity in comparison to other disease states.” — Michael Manolakis“Employers need to be thinking about cost, the prevalence of the condition, and fairness from a cost management perspective.” — Michael Manolakis